Moreover, H19 levels, when combined with N‐terminal proBNP (NT‐proBNP) levels or risk scores from the Registry to Evaluate Early and Long‐term PAH Disease Management (REVEAL registry) and the 2015 European Pulmonary Hypertension Guidelines, help identify subgroups of patients with distinct prognoses [282]. This evidence concerns the gene H19 and pulmonary arterial hypertension.